Williams Kherkher - Gadolinium Attorneys Providing Background
The gadolinium attorneys at Williams Kherkher owe it to our clients to keep a close eye on any and all developments that could pertain to cases at hand. One of the issues in recent times that's reached the extremely prevalent status is the FDA's treatment of this substance, as the FDA not only sets basic standards for products on the market, but they also serve as a warning source for any products that could cause harm.
Given the history of the FDA's treatment of this substance, gadolinium attorneys everywhere need to be up-to-date on how this information could impact their cases and their clients. Below is a brief outline of the FDA's involvement with this substance, and if you've suffered as a result of exposure to this agent, contact the gadolinium attorneys at Williams Kherkher today for a free consultation.
June of 2006
In June of 2006, several events took place that gave rise to the added scrutiny that gadolinium now faces. First, GE Healthcare issued a letter to health care providers alerting them of alarming statistics regarding its gadolinium-containing product OMNISCAN and those with kidney problems that originated in Europe. However, the letter denied any proven causal relationship at the time. The FDA subsequently issued an alert, and then a full-blown health advisory.
December of 2006
Later that year, the FDA issued an informational press release with a more direct and alarming alert describing the potential link between contrast agents containing gadolinium and the development of NSF after reviewing several statistical studies that had been compiled.
Almost simultaneously, the FDA issued a Public Health Advisory, again reviewing the relevant statistics and alerting the entire public to the growing evidence that dangers existed for those with kidney problems having a gadolinium-containing agent injected into their systems for MRI's and MRA's. This was the most direct warning to date, but studies and investigations continue.
May of 2007
The FDA, in its strongest step to date, requested that a "black box warning" to be attached to certain contrasting agent products containing gadolinium alerting users of the potential for a those with kidney problems to contract a fatal disease.
Overall, much continues to happen in regards to gadolinium. However, the last thing you should do is wait for more results to surface. If you have kidney problems and have had a recent scan, ask your doctor if you were injected with gadolinium. If you have, contact a gadolinium attorney at Williams Kherkher today for a free consultation.